chevron_leftBack
As of 24 April 2025, Tetra Bio-Pharma Inc. has a market cap of $516.00 USD, ranking #39100 globally and #2338 in Canada. It ranks #3982 in the Healthcare sector, and #1334 in the Biotechnology industry.
Key Stats
Market Cap
$516.00USD
EBITDA (TTM)
-$9.35MUSD
Net Income (TTM)
-$29.84MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
Employees
33
Website
tetrabiopharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | - | - | - | - | - |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
TBPMQ
Tetra Bio Pharma Inc
ISIN: CA88166Y1007
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.0002 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.
